Premium
Edaravone inhibits the disease activity in rheumatoid arthritis
Author(s) -
Arii Kaoru,
Kumon Yoshitaka,
Ikeda Yukio,
Suehiro Tadashi,
Hashimoto Kozo
Publication year - 2006
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2006.00722.x
Subject(s) - edaravone , rheumatoid arthritis , medicine , free radical scavenger , randomized controlled trial , pharmacology , arthritis , oxidative stress
Summary A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone. Polyarthralgia improved with a reduction in serum C‐reactive protein concentration soon after the start of edaravone administration. The disease activity score 28 (DAS28) also decreased. Edaravone appears to be effective for the control of RA. The usefulness of this potentially novel therapeutic agent should be tested in a well designed randomized controlled trial.